Backs 2023 adjusted EBITDA view of $74.0M-$80.0M. “As we approach midyear 2023, our business remains strong, and we are pleased with the positive growth trajectory in our key commercial products. Through our well-trained and experienced sales force — made up of 50 reps on the hospital side of the business and 25 focused on oncology — for the quarter to date, Barhemsys and Byfavo have already topped the sales number posted in Q1 2023, and Pemfexy has achieved an 18% market share in early Q2. We are pleased to see these two assets gaining uptake in the hospital and reflecting the value we saw when we originally decided to make the acquisition,” stated Scott Tarriff, CEO. “The team is executing well on our plans to drive adoption of our products, and as we look to future growth beyond our current marketed offerings, we anticipate expanding the portfolio through pipeline success and potential acquisition,” concluded Tarriff.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EGRX:
- Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance
- Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
- Eagle granted QIDP designation for CAL02 by FDA
- Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual Meeting
- Eagle Pharmaceuticals Reports First Quarter 2023 Results